British Journal of Haematology · 1994 · 87 citations · 13 references
Life SciencesGeneticsHematologyCytogeneticsHematopathologyHuman GeneticsChromosomal AbnormalitiesChromosomal DisordersChromosome AberrationsHematologic MalignanciesMolecular CytogeneticsNumerical Chromosome AbnormalitiesClassification CriteriaDna In Situ HybridizationLeukemia ClassificationLeukemia CytogeneticsMetaphase Chromosome AnalysisNegativityNeoplastic CytogeneticsNeoplastic Disease
The incidence of trisomy 12 was studied by conventional chromosome analysis in 111 patients referred as B-cell chronic lymphocytic leukaemia (B-CLL). Fluorescent in situ hybridization (FISH) was also applied in 34 of those patients with either a normal karyotype or no analysable mitoses. By karyotyping, trisomy 12 was present in 11.7% (13/111), whereas additional FISH increased the incidence to 14.4% (16/111). When subdividing our cases in either typical CLL (n = 90), fulfilling the FAB classification criteria, or atypical CLL (n = 21), with one or more variations from those criteria, the incidence of +12 by metaphase analysis was 3% and 48%, respectively. Additional FISH increased the incidence to 4% and 57%. The most common aberration in atypical CLL was FMC7 positivity (n = 11), followed by CD5 negativity (n = 8), strong surface immunoglobulin staining (n = 7) and atypical morphology (n = 6). Trisomy 12 could only be demonstrated in a small proportion of neoplastic cells in all positive cases. By FISH and/or karyotyping, all available samples at diagnosis of the disease were positive.
13
Guillaume Dighiero, P Travade, Sylvie Chevret et al. · Blood · 1991 · 289 citations · Full text
Medicine, Hematology, Oncology +13
Human B cell development. II. Subpopulations in the human fetus.
M Bofill, G Jánossy, M Jánossa et al. · The Journal of Immunology · 1985 · 258 citations